Amgen to spend $13.4B on Celgene psoriasis drug Otezla
Celgene will unload the psoriasis treatment Otezla for $13.4 billion to help make its acquisition by fellow drugmaker Bristol-Myers pass regulatory muster. The company plans to sel…
Celgene will unload the psoriasis treatment Otezla for $13.4 billion to help make its acquisition by fellow drugmaker Bristol-Myers pass regulatory muster. The company plans to sel…
